BioDrugs

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
Ira Jacobs*, Reginald Ewesuedo, Sadiq Lula, Charles Zacharchuk
*Corresponding author: Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755 USA Email: ira.jacobs@pfizer.com

Supplementary Table S2. NICE STA critical appraisal for randomized controlled trials

		How is the question	Grade
		addressed in the	(yes / no /
Category	Study question	study?	not clear)
Randomization	Was randomization carried out		
	appropriately?		
	Was the concealment of treatment		
	allocation adequate?		
Baseline	Were the groups similar at the outset of the		
characteristics	study in terms of prognostic factors, for		
	example, severity of disease?		
Blinding	Were the care providers, participants, and		
	outcome assessors blind to treatment		
	allocation? If any of these people were not		
	blinded, what might be the likely impact on		
	the risk of bias (for each outcome)?		
Withdrawals	Were there any unexpected imbalances in		
	drop-outs between groups? If so, were they		
	explained or adjusted for?		
Outcome	Is there any evidence to suggest that the		
selection and	authors measured more outcomes than		
reporting	they reported?		
Statistical	Did the analysis include an intention-to-treat		
analysis	analysis? If so, was this appropriate and		
	were appropriate methods used to account		
	for missing data?		